Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|January 4, 2016
Pfizer Depression Candidate Fails in Phase 3 Study
January 04, 2016.
Advertisement
FDA News reports that Pfizer’s Phase 3 study of Pristiq, a treatment for major depressive disorder, failed to meet its primary objective of superiority versus placebo in a study evaluating the drug for children between the ages of 7 and 17.
This is the second Phase 3 study for pediatric patients receiving Pristiq that did not demonstrate superior efficacy versus placebo, according to FDA News.
Pristiq was approved in 2008 for the treatment of major depressive disorder in adults.
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5